Authors

Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Latest:

ASCO GI 2021: MRD Detection With ctDNA From Assays

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.

Jade E. Jones, MD

Jade E. Jones, MD, is a medical oncologist at Winship Cancer Institute and assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Latest:

Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Johannes Zakrzewski, MD

Latest:

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Alicia Morgans, MD, MPH

Alicia Morgans, MD, MPH, is a

Latest:

Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

Lillian L Siu, MD, FRCPC

Latest:

Dr Siu on the Rationale for Combining Petosemtamab With Pembrolizumab in HNSCC

Lillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.

Richard J. Bleicher, MD, FACS

Latest:

Fellows on Film: How To Market Yourself for a Fellowship

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.

Stephen Liu, MD

Stephen Liu, MD, is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Latest:

Patient Profile and Treatment Selection in ALK+ NSCLC

Panelists discuss individualized treatment selection based on age, comorbidities, and patient preferences in ALK-positive lung cancer.

Lipika Goyal, MD

Latest:

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Wendell Naumann, MD

Latest:

Future of Gynecologic Oncology: Integrating Antibody-Drug Conjugates and Novel Combinations Into the IO Sequencing Paradigm for Advanced EC

Panelists discuss how future therapies, such as antibody-drug conjugates (ADCs) and novel combination therapies, could enhance immuno-oncology (IO) sequencing by offering more targeted options for patients who have progressed on initial IO therapies, while addressing resistance mechanisms and improving overall treatment outcomes.

Matthew Lunning, DO, FACP

Latest:

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Evan T. Hall, MD, MPhil

Evan Hall, MD MPhil, is a medical oncologist who specializes in the treatment of skin cancers (including melanoma) and kidney cancer.

Latest:

Dr Hall on Unmet Needs in Later-Line RCC

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Alex Duval, MD, PhD

Latest:

Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

Gerhardt Attard, MD, PhD, FRCP

Gerhardt Attard

Latest:

Dr Attard on Niraparib/Abiraterone Acetate Plus Prednisone in mCRPC With HRR Alterations

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Cortney Eakin, MD

Latest:

Dr. Eakin on Racial Disparities in Uterine Cancer

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Frederick Lansigan, MD

Sasha Stanton, MD

Latest:

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.

Morgan Bayer

Latest:

Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

Christopher Morse, MD

Latest:

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

April Rose, MD

Latest:

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Joshua Strauss, MD

Latest:

Dr. Strauss on Future Research Directions in SCLC

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.